Strides Pharma Science Limited (BOM:532531)
844.70
-9.60 (-1.12%)
At close: Jun 19, 2025
Strides Pharma Science Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Net Income | 35,935 | -706.14 | -2,026 | -4,602 | 2,684 | Upgrade
|
Depreciation & Amortization | 1,923 | 2,123 | 2,301 | 2,162 | 1,888 | Upgrade
|
Other Amortization | - | 83.99 | 131.21 | 168.49 | 174.59 | Upgrade
|
Loss (Gain) From Sale of Assets | -40.95 | -14.32 | -41.07 | 41.9 | -23.38 | Upgrade
|
Asset Writedown & Restructuring Costs | 0.05 | 1,575 | 330.4 | 1,774 | - | Upgrade
|
Loss (Gain) From Sale of Investments | -1,021 | - | -656.07 | -558.62 | -241.01 | Upgrade
|
Loss (Gain) on Equity Investments | -18.37 | 1,757 | 2,853 | 1,108 | 978.19 | Upgrade
|
Stock-Based Compensation | 16.09 | 15.86 | 13.01 | -7.09 | 68.02 | Upgrade
|
Provision & Write-off of Bad Debts | 10.85 | 175.67 | 344.17 | 1.78 | 94.61 | Upgrade
|
Other Operating Activities | -28,323 | 2,788 | 1,773 | -767.15 | 2,471 | Upgrade
|
Change in Accounts Receivable | -516.33 | 390.9 | -3,474 | -587.95 | -1,248 | Upgrade
|
Change in Inventory | -2,170 | 307.04 | -81.38 | 281.86 | -4,140 | Upgrade
|
Change in Accounts Payable | 1,049 | -1,485 | -1,023 | -1,593 | 2,108 | Upgrade
|
Operating Cash Flow | 6,844 | 7,011 | 444.11 | -2,578 | 4,814 | Upgrade
|
Operating Cash Flow Growth | -2.38% | 1478.58% | - | - | 135.09% | Upgrade
|
Capital Expenditures | -2,425 | -1,182 | -949.38 | -1,434 | -2,975 | Upgrade
|
Sale of Property, Plant & Equipment | 681.03 | 888.06 | 72.58 | 753.74 | 39.58 | Upgrade
|
Cash Acquisitions | -78.77 | -58.78 | - | -2,195 | -78.86 | Upgrade
|
Divestitures | - | 66.69 | 5,193 | - | - | Upgrade
|
Investment in Securities | 331.75 | -765.96 | -1,561 | 1,569 | -2,449 | Upgrade
|
Other Investing Activities | 154.44 | 90.69 | 269.64 | 118.67 | 254.63 | Upgrade
|
Investing Cash Flow | -896.89 | -1,503 | 3,025 | -1,187 | -5,208 | Upgrade
|
Short-Term Debt Issued | 422.34 | 2,424 | - | 4,564 | - | Upgrade
|
Long-Term Debt Issued | 1,291 | 1,073 | 3,304 | 4,507 | 5,675 | Upgrade
|
Total Debt Issued | 1,714 | 3,498 | 3,304 | 9,071 | 5,675 | Upgrade
|
Short-Term Debt Repaid | -2,030 | - | -504.55 | - | -1,824 | Upgrade
|
Long-Term Debt Repaid | -3,444 | -7,901 | -3,081 | -3,132 | -2,472 | Upgrade
|
Total Debt Repaid | -5,475 | -7,901 | -3,586 | -3,132 | -4,296 | Upgrade
|
Net Debt Issued (Repaid) | -3,761 | -4,403 | -281.82 | 5,939 | 1,378 | Upgrade
|
Issuance of Common Stock | 61.02 | 13.74 | 13.67 | 36.18 | 34.99 | Upgrade
|
Common Dividends Paid | -229.9 | -135.17 | - | -224.31 | -179.15 | Upgrade
|
Other Financing Activities | -2,496 | -2,409 | -1,871 | -1,538 | -1,392 | Upgrade
|
Financing Cash Flow | -6,426 | -6,933 | -2,139 | 4,213 | -157.96 | Upgrade
|
Foreign Exchange Rate Adjustments | -5.38 | 1.62 | 1.46 | 1.28 | -12.2 | Upgrade
|
Miscellaneous Cash Flow Adjustments | -0.22 | -1.35 | -3.39 | - | - | Upgrade
|
Net Cash Flow | -484.56 | -1,425 | 1,328 | 448.96 | -564 | Upgrade
|
Free Cash Flow | 4,419 | 5,829 | -505.27 | -4,012 | 1,840 | Upgrade
|
Free Cash Flow Growth | -24.20% | - | - | - | 235.77% | Upgrade
|
Free Cash Flow Margin | 9.68% | 14.39% | -1.37% | -13.07% | 5.55% | Upgrade
|
Free Cash Flow Per Share | 48.02 | 64.06 | -5.61 | -44.70 | 20.50 | Upgrade
|
Cash Interest Paid | 2,496 | 2,922 | 2,242 | 1,538 | 1,394 | Upgrade
|
Cash Income Tax Paid | -670.39 | -242.47 | -876.45 | -23.28 | -1,568 | Upgrade
|
Levered Free Cash Flow | 1,933 | 2,600 | 2,939 | -8,600 | -971.5 | Upgrade
|
Unlevered Free Cash Flow | 3,488 | 4,305 | 4,299 | -7,689 | -194 | Upgrade
|
Change in Net Working Capital | -158.72 | -46.49 | -1,903 | 7,095 | 2,026 | Upgrade
|
Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.